InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,187.70
(
0.13%
)
US TECH 100
17,618.80
(
0.03%
)
Dow Jones
38,884.26
(
0.08%
)
Brent Oil
81.90
(
-1.17%
)
Bitcoin
62,324.50
(
-0.02%
)
Post# of 251748
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 829
Posts 119591
Boards Moderated 14
Alias Born 09/05/2002

DewDiligence

Member Level

Re: biocqr post# 223637

Monday, 07/27/2020 10:59:00 AM

Monday, July 27, 2020 10:59:00 AM

Post# of 251748
TCRR +32% on preliminary phase-1 data:

https://www.globenewswire.com/news-release/2020/07/26/2067629/0/en/TCR-Therapeutics-Announces-RECIST-Responses-with-First-TC-210-Dose-Tested-in-Advanced-Mesothelin-Expressing-Solid-Tumors.html

TCR2 Therapeutics…today announced positive interim data from the first five patients treated in the Phase 1 portion of the TC-210 Phase 1/2 clinical trial for mesothelin-expressing solid tumors. All five patients showed tumor regression including two RECIST unconfirmed partial responses (one of which remains subject to independent central review) and two patients with stable disease through six months. Translational data further demonstrated TRuC-T cell expansion and activation. A manageable toxicity profile was observed…

Caveat emptor re unconfirmed RECIST responses, which are technically not supposed to be counted as responses.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up